Observational Study Links Metformin to 53% Lower Risk of Long COVID or Death

Research published in the Journal of Medical Virology in November 2026 indicates that adults prescribed metformin shortly after a COVID-19 infection had a 53% lower adjusted relative risk of developing long COVID or dying within six months, compared to those prescribed other medications. This observational study, which used electronic health records and a target trial emulation method, suggests a potential role for metformin in reducing long-term COVID-19 consequences. However, the authors caution that the findings do not establish direct prevention and further evidence on effectiveness and safety is needed before routine use for COVID-19 prevention.